Kornimate/medical-research-clean huggingface dataset:
study evaluating the effects of toradol and lyrica for pain control after donor nephrectomy

Conditions: Pain, Postoperative

Summary: the investigators will assess how the use of toradol and pregabalin affects return to bowel function and see if there is a difference in length of hospital stay. narcotic use can affect bowel function so the investigators hypothesize that use of toradol will decrease delayed bowel function and aid in a patients discharge and reduction of hospital stay.

perioperative pain management is a significant challenge following surgery. many pathways contribute to perioperative pain, including nociceptive, inflammatory, and neuropathic sources. although opioids have long been a mainstay for perioperative analgesia, other non-opioid therapies have been increasingly used as part of a multimodal analgesic regimen to provide improved pain control while minimizing opioid-related side effects toradol (ketorolac tromethamine), is a nonsteroidal anti-inflammatory drug (nsaid), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level. anecdotal evidence has shown that the use of toradol (ketorolac) is safe in renal surgery patients. the study team aims to further evaluate this in a pilot study specifically in the population of patient who have donated their kidney in live kidney transplants. the study team will assess how the use of toradol affects return to bowel function and see if there is a difference in length of hospital stay. narcotic use can affect bowel function so the investigators hypothesize that use of toradol will decrease delayed bowel function and aid in a patients discharge and reduction of hospital stay. the study team will assess differences in visual analog pain scores and total narcotic consumption, whereas secondary endpoints of urine output, serum creatinine and hemoglobin levels to assess for efficacy and safety. pregabalin is prescribed for neuropathic pain. in many studies, preoperative administration of pregabalin reduced postoperative morphine consumption and early postoperative pain. there will be two arms of the study including: arm 1 (pure placebo group): placebo oral preop then saline placebo iv x 1 in the or, then saline placebo iv every 6 hours for 7 doses. arm 2: pregabalin 75mg oral preop, then ketorolac 30 mg iv x 1 in the or, then ketorolac 15 mg iv every 6 hours for 7 doses. toradol and lyrica will be used consistent with its fda approval in terms of dosing, route of administration, etc.

Eligibility criteria:
inclusion criteria: * patients anticipating donating a kidney in a live kidney donor transplant. exclusion criteria: * patients not receiving a donor nephrectomy * pregnant, lactating, or nursing mothers * medical allergies or history that would otherwise be contraindicated for of a non-steroidal anti-inflammatory drug.

Keywords: live kidney donor donor nephrectomy
ear temperature as predictor of rectal temperature measured with modern devices in the emergency department.

Conditions: Fever

Summary: ear thermometers are often requested to be used rather than rectal thermometer (gold standard) for measuring the body temperature, as this method is faster and more user friendly. former ear thermometers did not meet the required standards of accuracy for clinical use. however, a new generation of ear thermometers have been developed and widely used in the emergency departments in denmark. the devices have only been evaluated in two studies on adult populations, with conflicting results. this cross-sectional study will examine patients by measuring both ear and rectal temperature in the same patient at the same time on admission to an emergency department, to evaluate if temperature measured in the ear can be used as the standard temperature measurement.


Eligibility criteria:
inclusion criteria: * admission to emergency department exclusion criteria: * no rectum
lean seafood intake and postprandial metabolism

Conditions: Hyperlipidemias; Nutritional and Metabolic Diseases; Nutrition Disorders; Metabolic Diseases; Glucose Metabolism Disorders

Summary: despite numerous studies of meal components in humans, little is still known about how different meals influence on metabolism. the purpose of this study is to a gain knowledge of how a balanced test meal with either lean seafood (example:cod) or meat as the main protein source will: 1. affect the postprandial metabolism acutely (test-meal at beginning of the study) 2. affect the postprandial metabolism after 4 weeks controlled intervention (test meal at end of intervention period) 3. affect gut microbiota composition


Eligibility criteria:
inclusion criteria: * 18-65 years of age * caucasian exclusion criteria: * smoking * diabetes * hysterectomy * abnormal bleeding last 6 months * use of medication that affects lipid and glucose metabolism * large (\>10%) alteration in body-weight the last 6 months * chronic, metabolic or acute disease or major surgery within last 3 months * dietary incompatibility with calcium supplementation and/ or seafood consumption (allergy, intolerance, dislike)

Keywords: seafood meat egg milk postprandial lipid metabolism postprandial glucose metabolism triglycerides cholesterol postprandial incretins postprandial hormones
causes of health disparities in african americans with coronary artery disease on clopidogrel

Conditions: Coronary Artery Disease

Summary: african americans with coronary artery disease who have been prescribed clopidogrel (also known as plavix), an antiplatelet drug will be enrolled. the purpose of this study is to help identify why african americans are at an increased risk of having a major heart attack or stroke after a common procedure to open up blocked arteries with stents. the knowledge to be gained from this study includes: 1. a better understanding of the metabolism of the antiplatelet drug, clopidogrel, and abnormal platelet function in african americans; this understanding may provide a basis for potential future therapy 2. a better understanding of challenges to taking clopidogrel as prescribed by a doctor and opinions about a genetic test related to this medicine.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. sex: male and female 3. race: self-identified as african american 4. history of percutaneous coronary intervention in the past 12 months 5. currently taking aspirin and clopidogrel for at least one month and up to one year 6. english speaking exclusion criteria: 1. use of nonsteroidal anti-inflammatory drugs 2. pregnancy will be excluded in women of child-bearing potential using urine pregnancy test

Keywords: african american coronary artery disease anti platelet
psychological treatment in psychiatric inpatient care

Conditions: Compulsory Psychiatric Care Act; Psychosis; Acceptance & Commitment Therapy; Psychiatric Hospitalization; Psychiatric Disorder

Summary: this study aims to investigate the effect of a brief psychotherapeutic treatment intervention based on act, aimed specifically at the vulnerable group of patients in psychiatric 24-hour care treated according to lpt. the study aims to investigate whether a brief number of therapeutic sessions according to act during inpatient care produce positive effects on personally relevant life areas for a diagnostically mixed group of patients in a psychiatric intensive care unit.


Eligibility criteria:
inclusion criteria: * 18 years old or older. * treated according to the compulsory psychiatric care act. * meet the criterion of informed consent. exclusion criteria: * lack the cognitive ability to acquire the treatment intervention, such as impaired attention, memory, logic and reasoning, and also auditory and visual processing. this will be based on a clinical assessment by the ward team, including the attending psychiatrist and a clinical psychologist. * ongoing psychological treatment parallel to the admission.
early anatomical, physiological, and clinical changes in diabetic macular edema after intravitreal aflibercept injection

Conditions: Diabetic Macular Edema; Diabetic Retinopathy; Clinically Significant Macular Edema

Summary: this is a one month pre post intervention study. subjects with diabetic macular edema were given intravitreal anti vegf (aflibercept) injection. central retinal thickness, macular electrophysiology, and visual acuity were observed one week and one month after injection was given to the eye to describe early anatomical, physiological, and clinical changes. we hypothesized that changes to these outcomes can be found and documented.


Eligibility criteria:
inclusion criteria: * minimum age of 18 y.o. * diagnosed with type 1 or 2 diabetes mellitus * have either one of mild non-proliferative diabetic retinopathy (npdr), moderate npdr, severe npdr, or proliferative diabetic retinopathy with clinically significant macular edema according to early treatment for diabetic retinopathy study (etdrs) criteria * best corrected visual acuity between one meter finger counting to 6/12 (etdrs chart) * minimum central macular thickness by optical coherence tomography examination of 250 um * willing to participate and sign the informed consent. exclusion criteria: * ongoing pregnancy or planning to be pregnant for the next 6 months. * media opacity (e.g. corneal scar, corneal edema, cataract, vitreous hemorrhage) which make macular oct not possible * history of intraocular surgery in the last 6 months * vitreoretinal surface disorders e.g. epiretinal membrane, vitreoretinal traction * history of panretinal laser photocoagulation in the last 6 months * presence of iris neovascularization * history of eye trauma * hba1c level \> 10,0 % * any other contraindication(s) for intravitreal anti vegf injection.

Keywords: aflibercept diabetic macular edema electroretinogram central macular thickness etdrs
high flow nasal cannula versus bubble nasal cpap for the treatment of transient tachypnea of the newborn in infants ≥ 35 weeks gestation

Conditions: Transient Tachypnea of the Newborn

Summary: the primary objective is to determine whether high flow nasal cannula (hfnc) is a superior respiratory modality for neonates ≥36 weeks with transient tachypnea of the newborn (ttn) when compared to the standard of care modality (ncpap).

transient tachypnea of the newborn, fetal lung fluid retention causing poor lung compliance and atelectasis, is a common entity in neonates ≥ 36 weeks in our unit. currently our standard of care includes using the respiratory modality of bubble nasal continuous positive airway pressure (bncpap) to support these neonates during this illness. bncpap provides positive distending pressure to recruit alveoli and prevent atelectasis, however, it is associated with air leak (pneumothorax, pneumomediastinum), nasal irritation and necrosis, and intolerance. hfnc is another respiratory modality that uses high flow gas that also provides positive distending pressure and thus prevents atelectasis. this modality does not cause nasal irritation or necrosis and has a minimal risk of air leak. we postulate that hfnc is a superior modality to bncpap in treating neonates ≥ 36 weeks with ttn. this will be determined by comparing the duration of respiratory support (in hours) for newborns ≥ 36 weeks gestation with a diagnosis to ttn randomized to receive either ncpap or hfnc for respiratory care.

Eligibility criteria:
inclusion criteria: * gestational age ≥ 35 weeks * diagnosis of ttn, defined as respiratory rate \>60, presence of subcostal and /or intercostal retractions, nasal flaring, grunting, oxygen saturations 70-93% on room air, and radiological evidence of perihilar streaking and patchy infiltrates * admission to the nicu at mount sinai hospital within first 24 hours of life exclusion criteria: * gestational age \< 35 weeks * history of thick meconium stained fluid and/or diagnosis of meconium aspiration syndrome * diagnosis of major congenital pulmonary or cardiac anomalies * initial cxr demonstrating air leak * respiratory distress first occurring after 24 hours of life * presumptive diagnosis of rds as indicated by the need for fio2 \> 40%, severe retractions and grunting with poor air entry, and diffuse alveolar consolidation on chest radiograph

Keywords: transient tachypnea of the newborn high flow nasal cannula bubble nasal continuous positive airway pressure
urdu translation, validity and reliability of dyspnea 12 (d-12)

Conditions: COPD

Summary: dyspnea is a distressing symptom with pain like perception. the object of study is to translate a tool that measure overall dyspnea severity. although many scales are available to assess dyspnea but d12 is a clear reliable scale and is use full in clinical practice to assess dyspnea in terms of intensity, quality and emotional response.

aim of study is to translate a clinical validate of urdu version of d-12 in copds patients. the study will measure reliability \& validity of dyspnea in urdu version. no study has been conducted in our region to translate d-12 follow the proper cross culture adaptation. therefor the instrument will translate in our language adapting proper cross culture guidelines.

Eligibility criteria:
inclusion criteria: * patient age between 40-65 with diagnosis of copd * outpatient individual who are on follow up * healthy individual * those who can read and understand english and urdu as well. exclusion criteria: * patient with cognitive impairment or sensory disorder were exclude. * patient physical disability * refuse to perform test

Keywords: body mass index (bmi) rate of perceived exertion (rpe) 6 minute walk test (^mwt)
early administration of bifidobacterium to very low birth weight infants

Conditions: Preterm Infants

Summary: to evaluate the effects of early administration of probiotics on acceleration of enteral feeding, and on growth of very low birth weight infants, newborn infants with birth weight less than 1500g are administered bifidobacterium bifidum twice a day.


Eligibility criteria:
inclusion criteria: * very low birth weight infant exclusion criteria: * presence of major congenital malformations

Keywords: bifidobacterium bifidum very low birth weight infant enteral feeding growth amount of enteral feeding
a post-marketing surveillance to assess the safety and effectiveness of zirabev in domestic patients with various cancer

Conditions: Non-small Cell Lung Cancer; Metastatic Colorectal Cancer; Metastatic Breast Cancer; Metastatic Kidney Cancer; Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer

Summary: this is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of zirabev(bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.


Eligibility criteria:
- inclusion criteria patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. adults over 19 years old 2. patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme. 3. patients eligible for zirabev dosage based on local product document, local treatment guidelines and clinical judgment of the medical team. 4. evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. * exclusion criteria patients meeting any of the following criteria will not be included in the study: 1. any patients (or a legally acceptable representative) who does not agree that pfizer and companies working with pfizer use his/her information. 2. patients for whom zirabev is contraindicated according to the local product document.

Keywords: zirabev
impact of renal replacement therapy on coagulation profile of patients with acute renal failure

Conditions: Acute Renal Failure; Hemorrhage; Coagulation Disorder

Summary: renal failure and high plasmatic level of urea have been associated with an increased risk of hemorrhage in surgical patients. there is only sparse data on the impact of renal replacement therapy on homeostatic parameters. the aim of this study is to describe potential changes in homeostatic parameters before and after renal replacement therapy.


Eligibility criteria:
inclusion criteria: * critically ill patients * acute renal failure * renal replacement therapy * plasmatic urea \> 20 exclusion criteria: * chronic renal failure * platelet count less than 80 giga * v factor less than 70%

Keywords: renal replacement therapy acute renal failure coagulation bleeding
investigation of the effect of central sensitization (cs) on steroid injection response in rotator cuff lesion

Conditions: Central Sensitisation; Subacromial Impingement Syndrome

Summary: the goal of this clinical trial is to learn whether pretreatment central sensitization presence affect shoulder steroid injection resuls in patients with rotator cuff pathology. the main questions it aims to answer are: 1. is central sensitization associated with decreased treatment response? 2. do the clinical features of patients with central sensitization differ from those of those without? participants will be applied a shoulder injection and the treatment response will be monitored.

shoulder pain is one of the most common musculoskeletal complaints and its prevalence varies between 7-26%. one of the most common sources of pain in these patients is subacromial impingement syndrome leading to rotator cuff pathology. in patients with shoulder pain, one of the factors associated with the persistence of pain in different etiologies, especially subacromial impingement syndrome, is reported as central sensitization (cs). cs can be summarized as an increase in the response of neurons located in the central nervous system to sub-threshold stimuli. in a meta-analysis of patients with shoulder pain, a decrease in pressure pain threshold was found in 29-77% of patients, and cs in 11-24%. there is increasing data showing that cs negatively affects response to different treatments, including surgery and injections. one of the most frequently used treatments in subacromial impingement syndrome is subacromial/intra-articular shoulder injection. although various factors have been identified in the prediction of shoulder injection results, the effect of pain sensitization on these procedures is unknown. in this study, it is planned to investigate the effect of the presence and severity of pretreatment central sensitization on the results of the shoulder injection in patients with a rotator cuff lesion or subacromial impingement.

Eligibility criteria:
inclusion criteria: * rotator cuff pathology confirmed clinically and radiologically (usg/mri) * failure to respond to medical/physical treatment * agree to participate in the study exclusion criteria: * shoulder trauma and history of previous shoulder surgery * history of injection to the painful shoulder in the last 3 months * use of centrally acting drugs (antidepressants, pregabalin, gabapentin and myorelaxant etc.) * history of active cancer, systemic inflammatory disease, and infection * pregnancy

Keywords: central sensitisation central sensitization inventory subacromial impingement shoulder pain steroid injection
randomized, placebo-controlled trial of lubiprostone as a preparation for capsule endoscopy

Conditions: Inflammatory Bowel Disease

Summary: this investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy.

introduction of small bowel capsule endoscopy made available an unique technique for diagnostic evaluation of the gastrointestinal tract. after esophagogastroduodenoscopy and colonoscopy about 5% of bleeding cases remain unexplained and capsule endoscopy provides small bowel yield. capsule endoscopy has special application for evaluation of inflammation bowel disease and other small bowel conditions. several adjuncts are used to enhance the examination by improving cleansing preparation or propulsion. metoclopramide, tegaserod, simethicone, erythromycin, phosphates and polyethylene glycol (peg) colon cleansing agents have been tried and some show improved visualization or increased propulsion where more capsules reach to colonic cecum while still recording within the limits of its 8 hour battery. recently, our group had an observational report of our experience showing that either full bowel cleansing preparation or prokinetics such as metoclopramide or tegaserod enhanced visualization and functioning capsule transit to the colon. lubiprostone is a novel chloride channel activator that increases intestinal fluid secretion and motility. it is fda approved and indicated for treatment of chronic idiopathic constipation. this investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy. the fda approved 24 mcg constipation dose was chosen because other medications used in similar single dose in our pilot studies appear effective.

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * gi disorders, gi surgery, cardiac, renal, or hepatic insufficiency, severe diarrhea

Keywords: capsule endoscopy prokinetic lubiprostone normal volunteers